In this cohort of 1312 women with a BRCA1/2 GPV, after RRSO the breast cancer risk did not decrease for both BRCA1 (HR: 1.29, 95% CI: 0.81–2.05) and BRCA2 GPV carriers (HR: 1.13, 95% CI: 0.62–2.06) compared to pre-RRSO. This evidence concerns the gene BRCA1 and breast cancer.